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Background
Fucoidan, a fucose-rich polysaccharide isolated from
brown alga, is currently under investigation as a new anti-
cancer compound [1-4]. In the present study, fucoidan
extract (FE) from Cladosiphon navae-caledoniae Kylin was
prepared by enzymatic digestion. We investigated whether
a combination of FE with chemotherapeutic agents had
the potential to improve the therapeutic efficacy of cancer
treatment.
Materials and methods
Estrogen receptor (ER)-positive MCF-7 and ER-negative
MDA-MB-231 breast cancer cells were cultured in DME
medium supplemented with 10% fetal bovine serum in a
humidified atmosphere of 5% CO2 at 37 °C. The abalone
glycosidase-digested fucoidan extract (FE) was obtained
from Daiichi Sangyo Corporation (Osaka, Japan). The
cells were treated with FE and chemotherapeutic agents
like cisplatin, tamoxifen or paclitaxel. The cell growth
was determined by MTT assay. Apoptosis was evaluated
using annexin V binding assay and flow cytometry analy-
sis. Signaling proteins were analyzed by western blot.
Intracellular reactive oxygen species (ROS) were deter-
mined using DCFH-DA and determined using IN Cell
Analyzer 1000. The reduced glutathione (GSH) concen-
tration was measured by the GSH assay kit.
Results
The co-treatments significantly induced cell growth inhi-
bition, apoptosis, as well as cell cycle modifications in
MDA-MB-231 and MCF-7 cells. FE enhanced apoptosis
in cancer cells that responded to treatment with cisplatin,
tamoxifen, or paclitaxel after 48 h of treatment (Figure 1).
FE enhanced the downregulation of the anti-apoptotic
proteins Bcl-xL and Mcl-1 by these chemotherapeutic
drugs. The combination treatments led to an obvious
decrease in the phosphorylation of ERK and Akt in
MDA-MB-231 cells, but increased the phosphorylation
of ERK in MCF-7 cells. In addition, we observed that
combination treatments enhanced intracellular ROS
levels and reduced glutathione (GSH) levels in breast
cancer cells, suggesting that induction of oxidative stress
was an important event in the cell death induced by the
combination treatments.
FE protected normal human fibroblast TIG-1 cells
from apoptosis by cisplatin and tamoxifen, suggesting its
favorable characteristic for application to cancer therapy.
Conclusions
• Combination of FE and three chemotherapeutic
agents exhibit highly synergistic inhibitory effects on
the growth of breast cancer cells.
• Combination treatments induced modifications in
cell cycle distribution.
• Combination treatments modified the Bcl-2
expression, and ERK and Akt phosphorylation
induced by FE, demonstrating different effects on
apoptotic pathways in MDA-MB-231 cells and
MCF-7 cells.
• Generation of intracellular ROS and depletion of
GSH are related to the cell death in combination
treated -breast cancer cells.
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Figure 1 Synergistic induction of apoptosis by co-treatmentAnalysis of apoptotic cells by annexin/PI double-staining using theIN Cell
Analyzer 1000. MDA-MB-231 and MCF-7 cells were treatedfor different times with 200 μg/mL FE alone or 200 μg/mL FEin combination with 5
μM CDDP, 10 μM TAM or 2.5 nM TAXOL after 48 h of treatment. All results were obtained from three independent experiments. A significant
difference from control is indicated by p < 0.05 (#) or p < 0.01 (##); a significant difference from single treatments is indicated by p < 0.05 (*) or
p < 0.01 (**).
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